Samsung Biologics and Kurma Partners announce collaboration for development and manufacturing of biologics
Betsy Goodfellow | October 24, 2023 | News story | Business Services |Â Â Kurma Partners, Pharmacy, Samsung BioLogicsÂ
Samsung Biologics and Kurma Partners have announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies. Kurma Partners is a European venture capital firm in healthcare and biotechnology, while Samsung Biologics is a global contract development and manufacturing organisation (CDMO).
Under the terms of this agreement, Samsung Biologics is expected to provide customisable chemistry, manufacturing and control (CMC) development services for Kurma Partners’ portfolio companies in order to streamline the gene to Investigational New Drug (IND) process, de-risk uncertainties in CMC and accelerate the lead candidate selection to entry into first-in-human studies while improving transitions along further clinical development.
Kurma’s companies are expected to utilise Samsung Biologics’ state-of-the-art facilities, proprietary technology and CMC expertise.
John Rim, president and chief executive officer of Samsung Biologics, commented: “As we look to further expand our business opportunities globally, we are pleased to collaborate with Kurma Partners to support the growth of pioneering biotech companies. With our in-depth knowledge on effective scale-up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance and ultimately maximise manufacturing efficiency for our clients.”
Betsy Goodfellow
Related Content
AstraZeneca and Samsung Biologics partner up in $330m manufacturing and supply deal
AstraZeneca has announced a new global manufacturing and supply partnership with Samsung Biologics, said to …
Samsung BioLogics delisted over accounting violations
South Korean firm Samsung BioLogics has been delisted from the South Korean stock exchange. The …
Samsung BioLogics’ shares down $6bn after accounting furore
Samsung BioLogics’ shares have been hit hard, after the South Korean company was handed a …
